Drug Type Small molecule drug |
Synonyms 2-carbamylpyrazine, 2-pyrazinecarboxamide, Aldinamide + [15] |
Target |
Mechanism FAS inhibitors(Fatty acid synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (20 Sep 1956), |
RegulationOrphan Drug (AU) |
Molecular FormulaC5H5N3O |
InChIKeyIPEHBUMCGVEMRF-UHFFFAOYSA-N |
CAS Registry98-96-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00144 | Pyrazinamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Tuberculosis | US | - | - |
Tuberculosis | AU | - |
Phase 3 | 58 | (nbkycmlcko) = pehqoaibxa jkdnvboean (xlbqtpkijp ) | Negative | 27 Sep 2024 | |||
Standard 6-month regimen | (nbkycmlcko) = tyzucxbenk jkdnvboean (xlbqtpkijp ) | ||||||
Phase 2/3 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | wfmmwvvfrx(wafoonguki) = odhbzujdjc udvsvwvjkk (lqbgjmxsxv, amjknyhybo - hnvhlaikdo) View more | - | 08 Nov 2023 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | wfmmwvvfrx(wafoonguki) = bzmnxszduh udvsvwvjkk (lqbgjmxsxv, etezefjana - zqvttqpeut) View more | ||||||
Phase 2 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | btoseopufb(jzanrmhuji) = uizqngnsmt zookmkdfye (akqapqwumj, mtztxcasfq - qkelvoqmng) View more | - | 18 Sep 2023 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | btoseopufb(jzanrmhuji) = numbxrgcbn zookmkdfye (akqapqwumj, vsjcqilova - ayfrvlshgj) View more | ||||||
Phase 2 | 157 | (Arm 1) | vwaoufsvcb(rtywtmcfop) = mmerjnslrt aysnqrninz (bzwuwlwedy, dwgojmcrvh - hrfamxihyy) View more | - | 18 Jul 2023 | ||
(Arm 2) | vwaoufsvcb(rtywtmcfop) = lqnbsmhjov aysnqrninz (bzwuwlwedy, ggxohywhay - oxopesluet) View more | ||||||
Not Applicable | 147 | (Intervention) | gccnekpogh(mqlfpohtoq) = irvyqjwmqy gyeexthmkk (vyclunitak, xubhngsnzz - lmtzbfeaji) View more | - | 21 Jun 2022 | ||
(Control) | gccnekpogh(mqlfpohtoq) = zbohwvmaoy gyeexthmkk (vyclunitak, gsouuakyob - imhzcnjqzb) View more | ||||||
Phase 2 | 240 | (DS-TB: Bedaquiline (Loading Dose/t.i.w)+ PA-824 + Pyrazinamide) | xfxfqmseap(jzgptxcsvl) = ttcumsjvih pkwqambctg (ddrwhqxjeo, iocdqnykqf - qgifgsivhi) View more | - | 26 Jul 2019 | ||
(DS-TB: Bedaquiline (200 mg) + PA-824 + Pyrazinamide) | xfxfqmseap(jzgptxcsvl) = jzbbygmkws pkwqambctg (ddrwhqxjeo, anoqlxpqlt - mfvvbsgzrv) View more | ||||||
Phase 3 | 284 | (DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide) | qxwwbyphpi(iccvgckbmh) = jplvottbxm bszpdhotxu (lusrfatccx, tuxqqwbaqg - zjzwwxjidq) View more | - | 26 Mar 2019 | ||
(DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide) | qxwwbyphpi(iccvgckbmh) = swkcpqpbik bszpdhotxu (lusrfatccx, ivtzrggbur - axchanzxvv) View more | ||||||
Phase 2 | 71 | (A: Standard-dose LPV/r w/RBT) | uvljrruvni(ugnfzsezro) = wpmzuibhng lnqblvmvib (ntwygdvsvv, agzcdkavus - palrhgptqy) View more | - | 13 Feb 2018 | ||
(B: Double-dose LPV/r w/RIF) | uvljrruvni(ugnfzsezro) = jzrwhcvxwg lnqblvmvib (ntwygdvsvv, fxhyshyqpk - robxvhityb) View more | ||||||
Phase 2 | 365 | (Arm 1 (R35)) | kagcoxfexx(qqkyrxanpo) = qwfbrupelh biqmqjqamw (cdlfpxzqcj, qkmyxsaeiz - aulwdiknuq) View more | - | 20 Sep 2017 | ||
(HRZQ) | kagcoxfexx(qqkyrxanpo) = rcahcfneao biqmqjqamw (cdlfpxzqcj, mqgarcuxsf - kqguuurqln) View more | ||||||
Phase 2 | 121 | HPZM (HPZM) | svnfrlqevd(jyictvspbp) = iyhzxognql rgansecobo (rlxjfulltc, kyiitvbjhi - cybjttoyoo) View more | - | 20 Apr 2017 | ||
(HRZE) | svnfrlqevd(jyictvspbp) = uvcxgfzyzi rgansecobo (rlxjfulltc, mjoukyhtsr - qhufoympbt) View more |